Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen)

Cancer Investigation

Volumn 21, Issue 1, 2003, Pages 14-20

  Louvet, Christophe ^a   Carrat, Fabien ^a   Mal, Frédéric ^b   Mabro, May ^a   Beerblock, Karine ^a   Vaillant, Jean Christophe ^a   Cady, Jean ^c   André, Thierry ^d   Gamelin, Erick ^e   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT MUTUALISTE MONTSOURIS   (France)

^c Clinique Geoffroy Saint Hilaire   (France)

^d HÔPITAL TENON   (France)

^e CENTRE PAUL PAPIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEG ISCHEMIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; STROKE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYDROXYUREA; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASES; LEUCOVORIN; LIFE TABLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WEIGHT GAIN;

EID: 0037217283     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120016399     Document Type: Article

References (19)

1. Pyrhönen, S.; Kuitinen, T.; Nyandoto, P.; et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 1995, 71, 587-591.
2. Murad, A.; Santiago, F.; Petroianu, A.; et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993, 72, 37-41.
3. Glimelius, B.; Hoffman, K.; Haglund, U.; et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann. Oncol. 1994, 5, 189-190.
4. de Gramont, A.; Bosset, J.F.; Milan, C.; et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997, 15, 808-815.
5. Louvet, C.; de Gramont, A.; Demuynck, B.; et al. Highdose folinic acid, 5-fluorouracil bolus and continuous infusion in poor prognosis patients with advanced measurable gastric cancer. Ann. Oncol. 1991, 2, 231-233.
6. Livingston, R.B.; Carter, S.K. Single agents in cancer chemotherapy; IFI/Plenum: New York, 1970.
7. Hoshino, T.; Nagashima, T. Factors modifying cytotoxicity induced by 5-FU and hydroxyurea. Cancer Treat. Rep. 1985, 69, 993-997.
8. de Gramont, A.; Louvet, C.; Bennamoun, M.; et al. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J. Infus. Chemother. 1996, 6, 97-101.
9. Johnston, P.G.; Geoffrey, F.; Drake, J.; Voeller, D.; Grem, J.L.; Allegra, C.J. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur. J. Cancer 1996, 32A (12), 2148-2154.
10. Albain, K.S.; Swinnen, L.J.; Erickson, L.C.; et al. Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience. Semin. Oncol. 1992, 19 (3 suppl 9), 102-109.
11. Miller, A.B.; Hoogstratten, B.; Staquet, M.; et al. Reporting results of cancer treatment. Cancer 1981, 47, 2507-2514.
12. Kaplan, E.I.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53, 5457-5481.
13. Cox, D.R. Regression models and life-tables. J. R. Stat. Soc. 1972, 34B, 187-220.
14. Wils, J.A.; Klein, H.O.; Wagener, D.J.; et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastro-Intestinal Tract Cancer Cooperative Group. J. Clin. Oncol. 1991, 9, 827-831.
15. Kim, N.K.; Park, Y.S.; Heo, D.S.; et al. A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993, 71, 3813-3818.
16. Cocconi, G.; Bella, M.; Zironi, S.; et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. 1994, 12, 2687-2693.
17. Kelsen, D.; Atiq, O.; Saltz, L.; et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment in gastric cancer. J. Clin. Oncol. 1992, 10, 541-548.
18. Wilke, H.; Wils, J.; Rougier, P.; et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. Proc. Am. Soc. Clin. Oncol. 1995, 14, 206 (abstract).
19. Webb, A.; Cunningham, D.; Scarffe, J.H.; et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J. Clin. Oncol. 1997, 15, 261-267.